---
input_text: 'Biochemical and imaging surveillance in germline TP53 mutation carriers
  with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.BACKGROUND:
  Carriers of a germline TP53 pathogenic variant have a substantial lifetime risk
  of developing cancer. In 2011, we did a prospective observational study of members
  of families who chose to either undergo a comprehensive surveillance protocol for
  individuals with Li-Fraumeni syndrome or not. We sought to update our assessment
  of and modify the surveillance protocol, so in this study we report both longer
  follow-up of these patients and additional patients who underwent surveillance,
  as well as update the originally presented surveillance protocol. METHODS: A clinical
  surveillance protocol using physical examination and frequent biochemical and imaging
  studies (consisting of whole-body MRI, brain MRI, breast MRI, mammography, abdominal
  and pelvic ultrasound, and colonoscopy) was introduced at three tertiary care centres
  in Canada and the USA on Jan 1, 2004, for carriers of TP53 pathogenic variants.
  After confirmation of TP53 mutation, participants either chose to undergo surveillance
  or chose not to undergo surveillance. Patients could cross over between groups at
  any time. The primary outcome measure was detection of asymptomatic tumours by surveillance
  investigations. The secondary outcome measure was 5 year overall survival established
  from a tumour diagnosed symptomatically (in the non-surveillance group) versus one
  diagnosed by surveillance. We completed survival analyses using an as-treated approach.
  FINDINGS: Between Jan 1, 2004, and July 1, 2015, we identified 89 carriers of TP53
  pathogenic variants in 39 unrelated families, of whom 40 (45%) agreed to surveillance
  and 49 (55%) declined surveillance. 19 (21%) patients crossed over from the non-surveillance
  to the surveillance group, giving a total of 59 (66%) individuals undergoing surveillance
  for a median of 32 months (IQR 12-87). 40 asymptomatic tumours have been detected
  in 19 (32%) of 59 patients who underwent surveillance. Two additional cancers were
  diagnosed between surveillance assessments (false negatives) and two biopsied lesions
  were non-neoplastic entities on pathological review (false positives). Among the
  49 individuals who initially declined surveillance, 61 symptomatic tumours were
  diagnosed in 43 (88%) patients. 21 (49%) of the 43 individuals not on surveillance
  who developed cancer were alive compared with 16 (84%) of the 19 individuals undergoing
  surveillance who developed cancer (p=0 012) after a median follow-up of 46 months
  (IQR 22-72) for those not on surveillance and 38 months (12-86) for those on surveillance.
  5 year overall survival was 88 8% (95% CI 78 7-100) in the surveillance group and
  59 6% (47 2-75 2) in the non-surveillance group (p=0 0132). INTERPRETATION: Our
  findings show that long-term compliance with a comprehensive surveillance protocol
  for early tumour detection in individuals with pathogenic TP53 variants is feasible
  and that early tumour detection through surveillance is associated with improved
  long-term survival. Incorporation of this approach into clinical management of these
  patients should be considered. FUNDING: Canadian Institutes for Heath Research,
  Canadian Cancer Society, Terry Fox Research Institute, SickKids Foundation, and
  Soccer for Hope Foundation.'
raw_completion_output: |-
  primary_disease: Li-Fraumeni syndrome

  medical_actions: clinical surveillance protocol; physical examination; biochemical studies; imaging studies; whole-body MRI; brain MRI; breast MRI; mammography; abdominal and pelvic ultrasound; colonoscopy; survival analyses

  symptoms: asymptomatic tumours; symptomatic tumours

  chemicals: 

  action_annotation_relationships: clinical surveillance protocol (including physical examination) TREATS asymptomatic tumours IN Li-Fraumeni syndrome; biochemical studies TREATS asymptomatic tumours IN Li-Fraumeni syndrome; imaging studies (including whole-body MRI; brain MRI; breast MRI; mammography; abdominal and pelvic ultrasound; colonoscopy) TREATS asymptomatic tumours IN Li-Fraumeni syndrome; survival analyses PREVENTS death IN Li-Fraumeni syndrome
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  survival analyses PREVENTS death IN Li-Fraumeni syndrome

  ===

extracted_object:
  primary_disease: MONDO:0018875
  medical_actions:
    - clinical surveillance protocol
    - MAXO:0000527
    - biochemical studies
    - imaging studies
    - whole-body MRI
    - MAXO:0000427
    - MAXO:0000431
    - MAXO:0010363
    - abdominal and pelvic ultrasound
    - MAXO:0001184
    - survival analyses
  symptoms:
    - asymptomatic tumours
    - symptomatic tumours
  action_annotation_relationships:
    - subject: clinical surveillance protocol (including physical examination)
      predicate: TREATS
      object: asymptomatic tumours
      qualifier: MONDO:0018875
    - subject: biochemical studies
      predicate: TREATS
      object: asymptomatic tumours
      qualifier: MONDO:0018875
    - subject: MAXO:0001184
      predicate: TREATS
      object: asymptomatic tumours
      qualifier: MONDO:0018875
    - subject: survival analyses
      predicate: PREVENTS
      object: death
      qualifier: MONDO:0018875
named_entities:
  - id: MONDO:0008891
    label: Brown-Vialetto-Van Laere syndrome
  - id: MAXO:0009004
    label: exome sequencing
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: HP:0002093
    label: respiratory insufficiency
  - id: HP:0010871
    label: sensory ataxia
  - id: HP:0000648
    label: optic atrophy
  - id: CHEBI:17015
    label: riboflavin
  - id: HP:0012469
    label: infantile spasms
  - id: HP:0000789
    label: infertility
  - id: HP:0005268
    label: miscarriage
  - id: CHEBI:16709
    label: pyridoxine
  - id: CHEBI:18405
    label: pyridoxal 5'-phosphate
  - id: CHEBI:27306
    label: vitamin B6
  - id: CHEBI:24041
    label: flavin mononucleotide
  - id: HP:0001250
    label: seizures
  - id: MONDO:0009974
    label: Familial hemophagocytic lymphohistiocytosis
  - id: MAXO:0010030
    label: bone marrow transplantation (BMT)
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:4911
    label: etoposide
  - id: MAXO:0000757
    label: infusion
  - id: CHEBI:41264
    label: busulfan (BU), cyclophosphamide (CP), etoposide (VP16), antithymocyte globulin
      (ATG)
  - id: MAXO:0000750
    label: conditioning regimen
  - id: CHEBI:73896
    label: gene therapy (GT)
  - id: MONDO:0009666
    label: Holocarboxylase synthetase deficiency
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: HP:0001942
    label: Metabolic acidosis
  - id: CHEBI:15956
    label: Biotin
  - id: HP:0003256
    label: Coagulopathy
  - id: CHEBI:48669
    label: Tranexamic acid
  - id: CHEBI:48675
    label: antifibrinolytic agents
  - id: MONDO:0020300
    label: Autosomal dominant nocturnal frontal lobe epilepsy
  - id: CHEBI:3387
    label: Carbamazepine
  - id: MONDO:0000903
    label: Myoclonus-dystonia
  - id: MAXO:0000943
    label: Deep Brain Stimulation
  - id: HP:0001252
    label: Hypotonia
  - id: MONDO:0005338
    label: Primary open-angle glaucoma (POAG)
  - id: MAXO:0001082
    label: Trabeculectomy
  - id: MAXO:0000960
    label: Viscocanalostomy
  - id: HP:0007906
    label: Elevated intraocular pressure (IOP)
  - id: HP:0000253
    label: Progressive microcephaly
  - id: HP:0001263
    label: Global developmental delay
  - id: HP:0000365
    label: Hearing loss
  - id: HP:0100785
    label: Insomnia
  - id: CHEBI:15681
    label: GM3
  - id: CHEBI:28892
    label: Ganglioside
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000950
    label: Supportive care
  - id: CHEBI:8378
    label: Prednisolone
  - id: MONDO:0015626
    label: Charcot-Marie-Tooth disease (CMT)
  - id: MAXO:0035087
    label: peripheral nerve biopsy
  - id: HP:0011096
    label: demyelination
  - id: HP:0001605
    label: vocal cord paralysis
  - id: MONDO:0007947
    label: Marfan's syndrome
  - id: HP:0001659
    label: aortic regurgitation
  - id: CHEBI:2904
    label: atenolol
  - id: CHEBI:6541
    label: losartan
  - id: MONDO:0004691
    label: Autosomal dominant polycystic kidney disease (ADPKD)
  - id: MAXO:0000004
    label: surgery
  - id: HP:0002586
    label: peritonitis
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0003546
    label: exercise intolerance
  - id: HP:0001332
    label: dystonia
  - id: HP:0001336
    label: myoclonus
  - id: HP:0001272
    label: cerebellar atrophy
  - id: HP:0002059
    label: cerebral atrophy
  - id: CHEBI:46245
    label: coenzyme Q10 (CoQ10)
  - id: MONDO:0009693
    label: multiple myeloma
  - id: HP:0002720
    label: IgA deficiency
  - id: HP:0006775
    label: multiple myeloma
  - id: MONDO:0011787
    label: Limb-girdle muscular dystrophy type 2I (LGMD2I)
  - id: MONDO:0009662
    label: Sly disease (mucopolysaccharidosis VII)
  - id: HP:0002321
    label: vertigo
  - id: HP:0040268
    label: recurrent infections of the middle ears
  - id: MONDO:0100137
    label: Telomere Diseases
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0001394
    label: Liver cirrhosis
  - id: HP:0002206
    label: Pulmonary fibrosis
  - id: HP:0003394
    label: Muscle cramps
  - id: CHEBI:4315
    label: Danazol
  - id: MONDO:0015286
    label: complete DiGeorge syndrome (cDGS)
  - id: MAXO:0010042
    label: Thymus transplantation
  - id: HP:0001973
    label: Autoimmune thrombocytopenia
  - id: HP:0100646
    label: Thyroiditis
  - id: HP:0001875
    label: Neutropenia
  - id: HP:0012378
    label: fatigue
  - id: MONDO:0010421
    label: X-linked Agammaglobulinemia
  - id: MONDO:0005180
    label: Parkinson disease
  - id: MONDO:0007765
    label: Hyperostosis cranialis interna
  - id: MONDO:0018997
    label: Noonan syndrome
  - id: HP:0004322
    label: short stature
  - id: MONDO:0015168
    label: arthrogryposis multiplex congenita
  - id: HP:0002828
    label: multiple joint contractures
  - id: HP:0034392
    label: joint contractures
  - id: MONDO:0010518
    label: Wiskott-Aldrich syndrome (WAS)
  - id: MAXO:0001077
    label: splenectomy
  - id: HP:0001873
    label: thrombocytopenia
  - id: MONDO:0011724
    label: Glut-1 deficiency syndrome
  - id: HP:0005484
    label: acquired microcephaly
  - id: HP:0001257
    label: spasticity
  - id: HP:0001251
    label: ataxia
  - id: HP:0011972
    label: hypoglycorrhachia
  - id: MONDO:0000188
    label: GLUT1 deficiency syndrome
  - id: HP:0001508
    label: Failure to thrive
  - id: HP:0000787
    label: Renal stones
  - id: CHEBI:37054
    label: 3-hydroxybutyrate
  - id: MONDO:0019353
    label: Stargardt disease
  - id: MONDO:0015974
    label: Severe combined immunodeficiency (SCID)
  - id: HP:0000964
    label: eczema
  - id: HP:0002960
    label: autoimmunity
  - id: HP:0001892
    label: hemorrhagic diathesis
  - id: MAXO:0000756
    label: transfusion
  - id: MONDO:0009561
    label: alpha-mannosidosis
  - id: HP:0003812
    label: clinical heterogeneity
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000011
    label: Physical therapy
  - id: MAXO:0000652
    label: Angiotensin-converting enzyme inhibitor therapy
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0010885
    label: Avascular necrosis
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: CHEBI:17334
    label: Penicillin
  - id: CHEBI:35457
    label: Angiotensin-converting enzyme inhibitors
  - id: HP:0001297
    label: stroke
  - id: CHEBI:35480
    label: analgesics
  - id: MONDO:0009061
    label: Cystic fibrosis
  - id: MONDO:0010926
    label: Familial Hypocalciuric Hypercalcemia type 3 (FHH3)
  - id: HP:0003072
    label: Hypercalcemia
  - id: HP:0002150
    label: Hypercalciuria
  - id: CHEBI:22984
    label: Calcium
  - id: MONDO:0018868
    label: Metachromatic leukodystrophy
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MAXO:0035059
    label: Nerve conduction studies
  - id: CHEBI:71418
    label: Triamcinolone acetonide
  - id: MONDO:0009216
    label: Fanconi-Bickel syndrome
  - id: MAXO:0000780
    label: Growth hormone therapy
  - id: CHEBI:37845
    label: Growth hormone (GH)
  - id: MAXO:0000088
    label: Dietary intervention
  - id: HP:0200134
    label: Epileptic encephalopathy
  - id: CHEBI:16704
    label: Uridine
  - id: MONDO:0005041
    label: Glaucoma
  - id: HP:0000618
    label: blindness
  - id: MONDO:0019234
    label: Peroxisome biogenesis disorder
  - id: HP:0001260
    label: Dysarthric speech
  - id: HP:0000958
    label: Dry skin
  - id: HP:0001284
    label: Absent reflexes
  - id: HP:0001083
    label: ectopia lentis
  - id: MONDO:0010626
    label: X-linked hyper-IgM syndrome
  - id: MONDO:0018875
    label: Li-Fraumeni syndrome
  - id: MAXO:0000527
    label: physical examination
  - id: MAXO:0000427
    label: brain MRI
  - id: MAXO:0000431
    label: breast MRI
  - id: MAXO:0010363
    label: mammography
  - id: MAXO:0001184
    label: colonoscopy
